InspireMD cuts warrant exercise price to USD 0.77, extends expiry to May 2028 or post-FDA approval window

InspireMD amended portions of its Series J and Series K warrants to align exercisability with expected FDA approval of CGuard Prime 80 cm.

• Changes cover about 4,800,000 Series J underlying shares and 9,500,000 Series K underlying shares held by participating holders.
• Amended warrants reset the exercise price to $0.77 per share, tied to the Sept. 18 close.
• Termination revised to the earlier of May 15, 2028 or 20 trading days after an FDA-approval announcement for CGuard Prime 80 cm.
• Full exercise could deliver up to $11 million in gross proceeds; no additional warrants were issued under the amendments.